BILAG Biologics Register

 Discovering more about new treatments for people with systemic lupus erythematosus.

 

 

What is the study?

 

The BILAG Biologics Register (BILAG BR) is a study underway at hospitals throughout the UK.

It is looking at the safety and effectiveness of biologic and biosimilar treatment for systemic lupus erythematosus (SLE).

What is biologic therapy?

Biologic drugs use substances that are made from living organisms, and use the body’s natural immune system to treat a disease.

This can be done by stimulating or suppressing part of the immune system to help the body fight the disease.

Who is eligible to join the study?

Patients are able to join the studies if they meet the following criteria:

  • They have a diagnosis of Systemic Lupus Erythematosus (SLE).
  • They are aged five years or older.

 

 

Depending on a number of criteria you will be put in one of two groups:

Biologic/biosimilar/targeted therapies group
Participants:
  • Must give informed consent within twelve months of starting the registration treatment.
  • Must be starting a biologic, biosimilar or targeted therapy .
  • Can have received other biologic/biosimilar/targeted therapies in the past.
Control group
Participants:
  • Must give informed consent within one month of starting the registration treatment.
  • Be starting a standard, immunosuppressive therapy:
    • Azathioprine
    • Mycophenolate Mofetil
    • Cyclophosphamide
    • Ciclosporin
    • Tacrolimus
  • Must be biologically naïve.
  • Are not eligible if only receiving methotrexate or hydroxychloroquine.

 

 

Information for study participants

Find out how to participate in the BILAG BR study.

Information for healthcare professionals

Find all the resources you need to process information about participants in BILAG BR.

The University of Manchester